文献速递肿瘤 PET/CT放射性药物与辐射防护

COVID-19患者18F-FDG PET/CT表现的演变:初步研究

Evolution of 18F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation.
PubMed 文献 · J Nucl Med · 2021-07-16

该回顾性研究纳入23例急性COVID-19、18例COVID-19后肺病(PCLD)及9例完全康复的18F-FDG PET/CT患者,以肺靶本比(TBRlung=SUVmax/SUVmin)评估肺部摄取随时间变化。急性期感染后3周内TBRlung与感染后时间强相关(rs=0.81,P<0.001),晚期显著高于早期(P=0.001);PCLD中接受高剂量类固醇者TBRlung较低(P=0.003),无症状者亦较低(P<0.001)。结论提示COVID-19肺部18F-FDG摄取随感染后时间增加,PCLD在病毒清除后摄取仍升高,提示持续炎症。

要点

  • 急性COVID-19感染后3周内,肺TBRlung与感染后时间强相关(rs=0.81,P<0.001)。
  • PCLD患者接受高剂量类固醇治疗者肺TBRlung较低(P=0.003)。
  • PCLD无症状患者肺TBRlung较低(P<0.001)。

核心结论

  • COVID-19患者肺部18F-FDG摄取随感染后时间增加。
  • PCLD患者在病毒清除后肺部18F-FDG摄取仍升高,提示持续炎症。
  • 接受类固醇治疗的PCLD患者肺部18F-FDG摄取较低。

研究设计与样本

  • 回顾性研究,利用医院临床电子记录识别英国疫情两个高峰期间的患者。
  • 纳入23例急性COVID-19、18例PCLD和9例完全康复的18F-FDG PET/CT患者。
  • 肺部18F-FDG摄取以肺靶本比(TBRlung=SUVmax/SUVmin)测量,并与时间分期比较。

主要发现

  • 急性COVID-19感染后3周内,TBRlung与感染后时间强相关(rs=0.81,P<0.001)。
  • 急性COVID-19晚期TBRlung显著高于早期(P=0.001)。
  • PCLD中接受高剂量类固醇治疗者TBRlung较低(P=0.003)。
  • PCLD无症状患者TBRlung较低(P<0.001)。

临床怎么用

  • 18F-FDG PET/CT可用于评估COVID-19及PCLD肺部炎症的时间演变。
  • PCLD患者病毒清除后肺部FDG摄取升高需考虑持续炎症可能。
  • 类固醇治疗可能降低PCLD患者肺部FDG摄取,解读时应结合治疗史。

局限性

  • 回顾性研究,样本量较小(急性23例、PCLD 18例、康复9例)。
  • 单中心研究,来自英国疫情两个高峰期间。
  • 未报告TBRlung的具体数值及组间比较的详细统计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to assess the temporal evolution of pulmonary 18F-FDG uptake in patients with coronavirus disease 2019 (COVID-19) and post-COVID-19 lung disease (PCLD). Methods: Using our hospital's clinical electronic records, we retrospectively identified 23 acute COVID-19, 18 PCLD, and 9 completely recovered 18F-FDG PET/CT patients during the 2 peaks of the U.K. pandemic. Pulmonary 18F-FDG uptake was measured as a lung target-to-background ratio (TBRlung = SUVmax/SUVmin) and compared with temporal stage. Results: In acute COVID-19, less than 3 wk after infection, TBRlung was strongly correlated with time after infection (rs = 0.81, P < 0.001) and was significantly higher in the late stage than in the early stage (P = 0.001). In PCLD, TBRlung was lower in patients treated with high-dose steroids (P = 0.003) and in asymptomatic patients (P < 0.001). Conclusion: Pulmonary 18F-FDG uptake in COVID-19 increases with time after infection. In PCLD, pulmonary 18F-FDG uptake rises despite viral clearance, suggesting ongoing inflammation. There was lower pulmonary 18F-FDG uptake in PCLD patients treated with steroids.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Thornton A, Fraioli F, Wan S, et al. Evolution of 18F-FDG PET/CT Findings in Patients After COVID-19: An Initial Investigation. J Nucl Med. 2021. PMID: 34272318. doi:10.2967/jnumed.121.262296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。